Deva Holding Past Earnings Performance
Past criteria checks 4/6
Deva Holding has been growing earnings at an average annual rate of 41.1%, while the Pharmaceuticals industry saw earnings growing at 10% annually. Revenues have been growing at an average rate of 48.3% per year. Deva Holding's return on equity is 15.9%, and it has net margins of 28.7%.
Key information
41.1%
Earnings growth rate
41.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 12.4% |
| Revenue growth rate | 48.3% |
| Return on equity | 15.9% |
| Net Margin | 28.7% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Deva Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 10,997 | 3,154 | 2,752 | 1,356 |
| 30 Jun 24 | 10,926 | 2,845 | 2,686 | 1,393 |
| 31 Mar 24 | 11,459 | 4,088 | 2,748 | 1,198 |
| 31 Dec 23 | 11,330 | 3,385 | 2,651 | 1,072 |
| 30 Sep 23 | 16,959 | 328 | 4,634 | 408 |
| 30 Jun 23 | 14,523 | 1,228 | 4,053 | 384 |
| 31 Mar 23 | 11,584 | -614 | 3,141 | 341 |
| 31 Dec 22 | 8,713 | 851 | 2,480 | 313 |
| 30 Sep 22 | 3,796 | 1,612 | 790 | 146 |
| 30 Jun 22 | 3,172 | 1,426 | 651 | 132 |
| 31 Mar 22 | 2,666 | 1,298 | 544 | 115 |
| 31 Dec 21 | 2,330 | 1,170 | 469 | 74 |
| 30 Sep 21 | 2,131 | 711 | 406 | 62 |
| 30 Jun 21 | 2,037 | 769 | 367 | 66 |
| 31 Mar 21 | 1,928 | 713 | 322 | 73 |
| 31 Dec 20 | 1,863 | 651 | 312 | 81 |
| 30 Sep 20 | 1,683 | 569 | 295 | 69 |
| 30 Jun 20 | 1,583 | 434 | 295 | 50 |
| 31 Mar 20 | 1,540 | 383 | 299 | 44 |
| 31 Dec 19 | 1,374 | 286 | 281 | 39 |
| 30 Sep 19 | 1,319 | 245 | 264 | 42 |
| 30 Jun 19 | 1,216 | 211 | 261 | 44 |
| 31 Mar 19 | 1,104 | 167 | 254 | 37 |
| 31 Dec 18 | 1,041 | 136 | 241 | 36 |
| 30 Sep 18 | 937 | 124 | 228 | 39 |
| 30 Jun 18 | 886 | 115 | 211 | 31 |
| 31 Mar 18 | 836 | 106 | 194 | 32 |
| 31 Dec 17 | 800 | 93 | 187 | 29 |
| 30 Sep 17 | 770 | 67 | 182 | 18 |
| 30 Jun 17 | 737 | 59 | 172 | 17 |
| 31 Mar 17 | 717 | 61 | 165 | 13 |
| 31 Dec 16 | 688 | 60 | 155 | 12 |
| 30 Sep 16 | 667 | 57 | 150 | 17 |
| 30 Jun 16 | 653 | 61 | 147 | 16 |
| 31 Mar 16 | 622 | 51 | 143 | 15 |
| 31 Dec 15 | 576 | 48 | 138 | 13 |
| 30 Sep 15 | 549 | 45 | 133 | 9 |
| 30 Jun 15 | 529 | 32 | 129 | 11 |
| 31 Mar 15 | 501 | 24 | 125 | 10 |
| 31 Dec 14 | 468 | 9 | 120 | 4 |
| 30 Sep 14 | 454 | 19 | 119 | 6 |
| 30 Jun 14 | 427 | 13 | 118 | 4 |
| 31 Mar 14 | 416 | 15 | 118 | 4 |
| 31 Dec 13 | 418 | 25 | 118 | 4 |
Quality Earnings: DEVA has a high level of non-cash earnings.
Growing Profit Margin: DEVA's current net profit margins (28.7%) are higher than last year (1.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DEVA's earnings have grown significantly by 41.1% per year over the past 5 years.
Accelerating Growth: DEVA's earnings growth over the past year (860.2%) exceeds its 5-year average (41.1% per year).
Earnings vs Industry: DEVA earnings growth over the past year (860.2%) exceeded the Pharmaceuticals industry 7.2%.
Return on Equity
High ROE: DEVA's Return on Equity (15.9%) is considered low.